Volume 5 | October 29, 2018
Kidney Cancer News Weekly
#GivingTuesday started as a way to give back to your community after the big shopping events of Black Friday and Cyber Monday. We hope that you'll consider donating to KCAN for your #GivingTuesday donation this holiday season.
Make Your Voice Heard in D.C.
Make your Voices Heard on Capitol Hill. Volunteers needed for our Advocacy day in Washington, D.C. on Dec. 4-5, 2018. If you are interested in attending, please register here.

Tuesday, Dec. 4 - Afternoon Arrival & Evening Briefing

Wednesday, Dec. 5 - Hill Briefing & Breakfast, Capitol Hill (House & Senate Visits)

Nature's 'kill code' may destroy cancer
Two recent studies detail a natural mechanism that, if harnessed properly, may be able to destroy cancer cells and their ability to become resistant to treatment — without any of the side effects of chemotherapy.

Dr. Grigg on the Future Treatment Landscape of Renal Cell Carcinoma
Keytruda-Inlyta Combo Extends Survival in Advanced Renal Cell Carcinoma Patients, Phase 3 Trial Shows
A combination of Keytruda (pembrolizumab) and Inlyta (axitinib) significantly extended the lives of patients with advanced renal cell carcinoma (RCC) and delayed disease progression or death, according to a Phase 3 clinical trial.

High Distress in Patients With Renal Cell Carcinoma, Call for Better Psychosocial Screening
A high prevalence of patients with renal cell carcinoma (RCC) reported distress in a cross-sectional study published in BJU International.1 The high prevalence was greater than what has been seen in other cancer types and highlights the need for better psychosocial screening of patients with RCC.

ESMO 2018 Conference Highlights:BMS' Opdivo Shines in Renal Cell Carcinoma Results
Data from the Phase III CheckMate -214 study was presented by Bristol-Myers Squibb at the European Society of Medical Oncology meeting over the weekend. The study results showed that the combination of two of BMS drugs was associated with significantly longer treatment-free survival (TFS) following discontinuation of the combination compared to discontinuation of sunitinib, the standard of care, in intermediate- and poor-risk RCC patients, the company said.

Half of all kidney cancer patients initially misdiagnosed
Half of all patients with kidney cancer are initially misdiagnosed, data from Kidney Cancer UK’s patient survey has revealed.

In 45% of patients surveyed the disease was first mistaken for less serious conditions such as a urine infection, kidney stones or respiratory problems, the charity said.

About KCAN
As the voice of kidney cancer advocacy in Washington, D.C. and across the U.S., we are committed to curing kidney cancer and other cancers now. We have been instrumental in obtaining $45,000,000 in research funding for Kidney Cancer through the CDMRP (Congressionally Dedicated Medical Research Program).

Please consider supporting our organization.

About The KCAN Weekly Newsletter
Using advanced technology, KCAN tracks over 400 keywords related to RCC on the interne t. This search includes Google and Google Scholar. On a weekly basis, we provide you with new articles from around the world related to RCC so you can be up-to-date and save precious hours searching the internet. The goal is to keep you healthy and informed with current, relevant information. See the "content" section below to learn more.

KCAN will publish this free weekly newsletter on Smartpatients during the first two weeks of each month, you will need to subscribe at KCAN.org by clicking the subscribe button to receive the rest of the months weekly newsletters.

Please sign up your friends for the newsletter, both patients and caregivers. Please sign up your oncologist to receive a copy.

If you have other ideas about items to be tracked please contact us.

Please post a link to our newsletter in the following places:
-Your Facebook and Twitter feeds
-Kidney Cancer chat rooms that you visit
The Content Behind the KCAN Newsletter
We track the following information for you:

-the top RCC institutions: MSKCC, DFCI, BIDMC, UTSW, etc.
-the top trials: NKTR, Pembo/Axi, Avel/Axi, HERVE-TCR, AM0010, Cabo/Nivo, Tivo, etc.
-the future: CAR NK, Microbiome, killer engagers, YAP, YAZ, CPG Oligonucleotide, TriKEs, etc.
-the top targets: CD 3 CD 40, CD 70, CD 73, etc.
-the top cancer biotech firms: Acro, Tikcro, Sutro, Regeneron, Batu,Peloton, etc.
-the top cancer genes: PBRM1, BAP1, EZH2, etc.
-the top conferences: ASCO, ESMO, AUA, AACR, SITC, ASTRO, etc.
-the top novel agents: HIF, Glutaminase, IL10, Adenosine, CXCR4, Neoantigen peptides, LAG3, etc.
-the top RCC surgeons and oncologists

If you want us to track something for you, send us an email.

Disclaimer: The material in this newsletter is for informational purposes only and is not a substitute for professional medical advice. consult with a qualified healthcare provider with any questions or concerns you may have.
| Kidney Cancer Action Network | Tel: 202-431-2727 | contact @KCAN. org | www.KCAN.org